BioMarin Pharmaceutical | BMRN - Ebit

Aktienkurs
55.95
Täglich Wechseln
0.45 0.81%
Monatlich
-8.10%
Jährlich
-5.43%
Q2 Prognose
53.83




Ebit Veränderung Datum
Acadia Pharmaceuticals USD 17.39M 18.36M 2025-12
Agios Pharmaceuticals USD -121.58M 4.71M 2025-12
Alnylam Pharmaceuticals USD 29.4M 59.36M 2025-12
Amgen USD 3.96B 464M 2025-12
Bayer EUR 1.11B 1.51B 2025-12
Biogen USD 659.6M 157M 2025-09
BioMarin Pharmaceutical USD 198.39M 230.08M 2025-12
Gilead Sciences USD 2.96B 551M 2025-12
Incyte USD 383.88M 47.44M 2025-12
Insmed USD -249.71M 11.64M 2025-12
Ionis Pharmaceuticals USD -215M 54.82M 2025-12
Moderna USD -857M 597M 2025-12
Neurocrine Biosciences USD 227.9M 11.4M 2025-12
PTC Therapeutics USD -81.62M 85.11M 2025-12
Puma Biotechnology USD -2.2M 11.41M 2024-06
Regeneron Pharmaceuticals USD 898.6M 211.3M 2025-12
Roche Holding CHF 9.56B 2.1B 2025-12
Sanofi EUR 3.74B 2.23B 2025-09
Sarepta Therapeutics USD -410.08M 347.2M 2025-12
Ultragenyx Pharmaceutical USD -114M 56.89M 2025-12
United Therapeutics USD -14.6M 403.9M 2025-12
Vertex Pharmaceuticals USD 1.26B 24.5M 2025-12